Polyiclc
Muscle-Invasive Bladder Carcinoma
Washington University School of MedicinePhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 95/ 100
Competitive context
2 Active assets in the Muscle-Invasive Bladder Carcinoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
CIS-DIAMMINEDICHLOROPLATINUM II Vasgene Therapeutics, Inc | Phase 2/3 | B |
Optimized Neoantigen Synthetic Long Peptide Vaccine Washington University School of Medicine | Phase 1 | CC |
Same molecule, other indications
Polyiclc is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →